BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37787838)

  • 1. An analysis of sintilimab combined with ruxolitinib as compassionate therapy for 12 adults with EBV-associated hemophagocytic lymphohistiocytosis.
    Xu Y; Li W; Gan J; He X; Huang X
    Ann Hematol; 2023 Dec; 102(12):3325-3333. PubMed ID: 37787838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sintilimab treatment for chronic active Epstein-Barr virus infection and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children.
    Chen R; Lin Q; Zhu Y; Shen Y; Xu Q; Tang H; Cui N; Jiang L; Dai X; Chen W; Li X
    Orphanet J Rare Dis; 2023 Sep; 18(1):297. PubMed ID: 37736751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
    Wang J; Wang Y; Wu L; Zhang J; Lai W; Wang Z
    J Hematol Oncol; 2016 Sep; 9(1):84. PubMed ID: 27613189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved hemophagocytic lymphohistiocytosis index predicts prognosis of adult Epstein-Barr virus-associated HLH patients.
    Yao S; He L; Zhang R; Liu M; Hua Z; Zou H; Wang Z; Wang Y
    Ann Med; 2023 Dec; 55(1):89-100. PubMed ID: 36533966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis.
    Zhang Q; Wei A; Ma HH; Zhang L; Lian HY; Wang D; Zhao YZ; Cui L; Li WJ; Yang Y; Wang TY; Li ZG; Zhang R
    Haematologica; 2021 Jul; 106(7):1892-1901. PubMed ID: 32732367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab treatment of relapsed/refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults.
    Liu P; Pan X; Chen C; Niu T; Shuai X; Wang J; Chen X; Liu J; Guo Y; Xie L; Wu Y; Liu Y; Liu T
    Blood; 2020 Mar; 135(11):826-833. PubMed ID: 31914172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ruxolitinib treatment for SR-aGVHD in patients with EBV-HLH undergoing allo-HSCT.
    Meng G; Wang J; Wang X; Wang Y; Wang Z
    Ann Hematol; 2020 Feb; 99(2):343-349. PubMed ID: 31879790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults and adolescents-a life-threatening disease: analysis of 133 cases from a single center.
    Lai W; Wang Y; Wang J; Wu L; Jin Z; Wang Z
    Hematology; 2018 Dec; 23(10):810-816. PubMed ID: 29957156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful Treatment of Relapsed Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis After Allo-HSCT with PD-1 Blockade: A Case Report.
    Pi Y; Wang J; Wang Z
    Infect Drug Resist; 2022; 15():3751-3756. PubMed ID: 35859915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children.
    Wei A; Ma H; Li Z; Zhang L; Zhang Q; Wang D; Lian H; Zhang R; Wang T
    Int J Hematol; 2020 Oct; 112(4):568-576. PubMed ID: 32666469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical analysis and follow-up study of Epstein-Barr virus associated-hemophagocytic lymphohistiocytosis in childhood].
    Lu G; Xie ZD; Shen KL; Wu RH; Jin YK; Yang S; Liu CY
    Zhonghua Er Ke Za Zhi; 2010 Feb; 48(2):121-6. PubMed ID: 20426937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematopoietic stem cell transplantation for familial hemophagocytic lymphohistiocytosis and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Japan.
    Ohga S; Kudo K; Ishii E; Honjo S; Morimoto A; Osugi Y; Sawada A; Inoue M; Tabuchi K; Suzuki N; Ishida Y; Imashuku S; Kato S; Hara T
    Pediatr Blood Cancer; 2010 Feb; 54(2):299-306. PubMed ID: 19827139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T Cell-Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis (HLH) Occurs in Non-Asians and Is Associated with a T Cell Activation State that Is Comparable to Primary HLH.
    Shamriz O; Kumar D; Shim J; Briones M; Quarmyne MO; Chonat S; Lucas L; Edington H; White MH; Mahajan A; Park S; Chandrakasan S
    J Clin Immunol; 2021 Oct; 41(7):1582-1596. PubMed ID: 34173902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ruxolitinib combined with liposomal doxorubicin, etoposide, methylprednisolone+/-PEG-asparaginase in treatment of relapsed/refractory pediatric hemophagocytic lymphohistiocytosis].
    Wei A; Ma HH; Zhang LP; Lian HY; Du JY; Wang D; Cui L; Ou WX; Zhao YZ; Zhao XX; Zhang L; Li ZG; Wang TY; Zhang R
    Zhonghua Yi Xue Za Zhi; 2022 Jul; 102(28):2167-2172. PubMed ID: 35872580
    [No Abstract]   [Full Text] [Related]  

  • 15. HLA-mismatched GPBSC infusion therapy in refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: an observational study from a single center.
    Song Y; Wang J; Wang Y; Wang Z
    Stem Cell Res Ther; 2020 Jul; 11(1):265. PubMed ID: 32611452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-DEP regimen salvage therapy for paediatric patients with refractory Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis.
    Zhao Y; Li Z; Zhang L; Lian H; Ma H; Wang D; Zhao X; Zhang Q; Wang T; Zhang R
    Br J Haematol; 2020 Nov; 191(3):453-459. PubMed ID: 32525580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rescue of HLH with T and B Lymphocyte Involvement Due to Epstein-Barr Virus by PD-1 Inhibitor/Ruxolitinib and Rituximab Combination Regimens: A Case Report.
    Zhu M; Zhang J; Shi Q; Sun X; Wang H; Sun M; Liu Y
    Iran J Immunol; 2023 Dec; 20(4):466-472. PubMed ID: 37873944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cord Blood Transplantation Following Reduced-Intensity Conditioning for Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis during Systemic Lupus Erythematosus Treatment.
    Kuriyama T; Kawano N; Yamashita K; Kikuchi I
    J Clin Exp Hematop; 2016; 56(2):126-129. PubMed ID: 27980302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus central nervous system involvement in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
    Yin Q; Wang J; Wang Z
    Ann Hematol; 2022 Nov; 101(11):2471-2476. PubMed ID: 36071294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary hemophagocytic lymphohistiocytosis in pediatric patients with visceral leishmaniasis and Epstein-Barr virus infection.
    Li Y; Li S; Lu N; Wang W; Wang D
    Ann Hematol; 2024 May; 103(5):1541-1547. PubMed ID: 38467825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.